LMAT (LeMaitre Vascular) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LMAT LeMaitre Vascular Inc LMAT
100 GF Score
Price $81.45
GF Value $95.26
Valuation Modestly Undervalued
View Full Analysis

What is LeMaitre Vascular Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of LeMaitre Vascular is: Low Risk: Strong fundamentals, worth long-term holding.

LeMaitre Vascular  (NAS:LMAT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

LeMaitre Vascular Risk Assessment Related Terms

LMAT vs PLSE, XRAY, ATRC: Risk Assessment Comparison

For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LeMaitre Vascular Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Risk Assessment distribution charts can be found below:

* The bar in red indicates where LeMaitre Vascular's Risk Assessment falls into.


LMAT
100GF Score
LeMaitre Vascular Inc LMAT
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is LeMaitre Vascular (LMAT) Overvalued in 2026?

Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued. The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26. GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.

Key valuation signals for LMAT:

  • Risk Assessment:
  • GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
  • GF Score™: 100/100

No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LeMaitre Vascular Business Description

Other Exchanges LHU:Germany
Address 63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score

Get the complete analysis for LMAT

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.45
Price
$95.26
GF Value